IR-502 synthetic peptides: IMNR completed enrollment in its Phase II trial

The Immune Response Corp. (IMNR), Carlsbad, Calif. Product: IR-502 synthetic peptides to turn off specific immune cells Indication: Psoriasis Status: IMNR completed enrollment in its Phase II trial in...